ADC Therapeutics (ADCT) Net Cash Flow Growth (1y) (2021 - 2026)
ADC Therapeutics (ADCT) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 53.46% |
| 10 | ADC Therapeutics | 174.95 Mn | -56.06 Mn | 17.38 Mn | 46.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.16% |
| Dec 31, 2025 | 215.45% |
| Sep 30, 2025 | -14.12% |
| Jun 30, 2025 | 5.89% |
| Mar 31, 2025 | -27.24% |
| Dec 31, 2024 | 27.84% |
| Sep 30, 2024 | 29.33% |
| Jun 30, 2024 | 78.37% |
| Mar 31, 2024 | -176.98% |
| Dec 31, 2023 | 41.53% |
| Sep 30, 2023 | -958.92% |
| Jun 30, 2023 | 168.40% |
| Mar 31, 2023 | 55.09% |
| Dec 31, 2022 | 14.16% |
| Sep 30, 2022 | -97.28% |
| Jun 30, 2022 | -379.44% |
| Mar 31, 2022 | 36.57% |
| Dec 31, 2021 | -15.03% |
| Sep 30, 2021 | 8.34% |
| Jun 30, 2021 | -104.23% |